Published in JAMA on February 22, 2012
Prevention of influenza at Hajj: applications for mass gatherings. J R Soc Med (2013) 1.95
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J (2015) 1.55
Pneumococcal conjugate vaccination for older adults: Reply letter to Hollingsworth et al. Hum Vaccin Immunother (2013) 1.54
Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ (2012) 1.23
Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant. Hum Vaccin Immunother (2016) 1.03
Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults. Am J Prev Med (2013) 0.98
Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum Vaccin Immunother (2013) 0.97
Prevention of pneumococcal infection with vaccines: an evolving story. JAMA (2012) 0.96
Invasive pneumococcal disease in healthy adults: increase of empyema associated with the clonal-type Sweden(1)-ST306. PLoS One (2012) 0.92
Pneumococcal conjugate vaccines for adults: reasons for optimism and for caution. Hum Vaccin Immunother (2014) 0.92
A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly. Hum Vaccin Immunother (2015) 0.91
Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis (2012) 0.86
Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults. Vaccine (2013) 0.86
Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission. PLoS One (2014) 0.82
Theory and strategy for Pneumococcal vaccines in the elderly. Hum Vaccin Immunother (2016) 0.80
Cost-effectiveness of strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in an intensive care unit. Infect Control Hosp Epidemiol (2015) 0.80
Cost-effectiveness of pneumococcal and influenza vaccination standing order programs. Am J Manag Care (2013) 0.79
Respiratory review of 2012: pneumonia. Tuberc Respir Dis (Seoul) (2012) 0.78
Preventing non bacteremic pneumococcal pneumonia in older adults: historical background and considerations for choosing between PCV13 and PPV23. Hum Vaccin Immunother (2014) 0.78
Non-invasive pneumococcal pneumonia in Portugal--serotype distribution and antimicrobial resistance. PLoS One (2014) 0.78
Cost-effectiveness of pneumococcal vaccines for adults in the United States. Adv Ther (2014) 0.78
Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States. J Gen Intern Med (2016) 0.78
Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly. PLoS One (2013) 0.77
Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain. Clin Drug Investig (2016) 0.75
Economic studies applied to vaccines against invasive diseases: an updated budget impact analysis of age-based pneumococcal vaccination strategies in the elderly in Italy. Hum Vaccin Immunother (2016) 0.75
How many individuals with asthma need to be vaccinated to prevent one case of invasive pneumococcal disease? Can J Infect Dis Med Microbiol (2014) 0.75
Role of pneumococcal vaccination in prevention of pneumococcal disease among adults in Singapore. Int J Gen Med (2014) 0.75
Cost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil. PLoS One (2015) 0.75
Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: A meta-analysis. Hum Vaccin Immunother (2016) 0.75
Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older. J Am Geriatr Soc (2016) 0.75
Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia. BMC Infect Dis (2014) 0.75
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep (2010) 10.59
How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ (1992) 10.40
Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation (1993) 9.24
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis (2010) 8.37
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med (2003) 7.39
Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet (2007) 5.50
Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA (2005) 5.29
What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care (2008) 5.14
Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ (2009) 4.38
Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care (1998) 4.04
Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis (2005) 3.72
Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev (2008) 3.13
United States life tables, 2006. Natl Vital Stat Rep (2010) 3.01
Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2010) 2.95
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J (2002) 2.94
Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med (2003) 2.87
Profile for estimating risk of heart failure. Arch Intern Med (1999) 2.81
Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis (2008) 2.72
Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep (2010) 2.71
Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep (2010) 2.52
Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio (2011) 2.48
Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med (1999) 2.21
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J (2006) 2.10
Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA (1999) 2.09
Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine (2011) 2.03
Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report. J Gen Intern Med (2003) 1.70
Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making (1994) 1.66
Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med (2008) 1.57
Clinical and economic burden of pneumococcal disease in older US adults. Vaccine (2010) 1.55
Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis (2008) 1.31
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
Factors associated with survival to 75 years of age in middle-aged men and women. The Framingham Study. Arch Intern Med (1996) 1.19
Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine (2008) 1.14
Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine (2002) 1.09
Demographics of the prevalence, incidence, and management of coronary heart disease in the elderly and in women. Ann Epidemiol (1994) 1.06
Prevalence of high-risk indications for influenza vaccine varies by age, race, and income. Vaccine (2010) 1.04
Community-acquired pneumonia. Curr Opin Pulm Med (2009) 1.01
Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine? Chest (2010) 1.00
Pneumococcal polysaccharide vaccination among adults aged 65 years and older, U.S., 1989-2008. Am J Prev Med (2010) 0.89
Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009. Am J Epidemiol (2012) 0.81
Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2009) 6.52
Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet (2007) 5.50
Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA (2009) 4.61
Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis (2013) 3.00
Sensitivity and specificity of patient self-report of influenza and pneumococcal polysaccharide vaccinations among elderly outpatients in diverse patient care strata. Vaccine (2003) 2.76
Simulating school closure strategies to mitigate an influenza epidemic. J Public Health Manag Pract (2010) 2.59
Vaccine criticism on the World Wide Web. J Med Internet Res (2005) 2.25
A computer simulation of employee vaccination to mitigate an influenza epidemic. Am J Prev Med (2009) 2.20
Seroprevalence following the second wave of Pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA. PLoS One (2010) 2.16
A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. Vaccine (2010) 2.13
What affects influenza vaccination rates among older patients? An analysis from inner-city, suburban, rural, and Veterans Affairs practices. Am J Med (2003) 2.12
Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. Clin Infect Dis (2010) 2.09
Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics (2002) 2.03
Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep (2015) 2.01
National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics (2006) 2.01
Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis (2008) 1.80
Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics (2008) 1.78
Emergence of parapneumonic empyema in the USA. Thorax (2011) 1.67
Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients. Infect Control Hosp Epidemiol (2008) 1.61
Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics (2007) 1.61
The 2000 tularemia outbreak: a case-control study of risk factors in disease-endemic and emergent areas, Sweden. Emerg Infect Dis (2002) 1.58
Vaccination deep into a pandemic wave potential mechanisms for a "third wave" and the impact of vaccination. Am J Prev Med (2010) 1.57
Impact of changing the measles vaccine vial size on Niger's vaccine supply chain: a computational model. BMC Public Health (2011) 1.57
Tailored interventions to increase influenza vaccination in neighborhood health centers serving the disadvantaged. Am J Public Health (2003) 1.55
An outbreak of gastrointestinal illness and erythema nodosum from grated carrots contaminated with Yersinia pseudotuberculosis. J Infect Dis (2006) 1.55
Missed opportunities for adult immunization in diverse primary care office settings. Vaccine (2004) 1.51
The impact of making vaccines thermostable in Niger's vaccine supply chain. Vaccine (2012) 1.48
Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med (2007) 1.46
Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014. MMWR Morb Mortal Wkly Rep (2014) 1.44
Impact of introducing the pneumococcal and rotavirus vaccines into the routine immunization program in Niger. Am J Public Health (2011) 1.39
International Circumpolar Surveillance System for invasive pneumococcal disease, 1999-2005. Emerg Infect Dis (2008) 1.34
Internet use and epidemiologic investigation of gastroenteritis outbreak. Emerg Infect Dis (2004) 1.32
Replacing the measles ten-dose vaccine presentation with the single-dose presentation in Thailand. Vaccine (2011) 1.29
The benefits to all of ensuring equal and timely access to influenza vaccines in poor communities. Health Aff (Millwood) (2011) 1.28
Barriers to pneumococcal and influenza vaccination in older community-dwelling adults (2000-2001). J Am Geriatr Soc (2004) 1.26
Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis (2009) 1.22
Physician and practice factors related to influenza vaccination among the elderly. Am J Prev Med (2004) 1.21
Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza. Vaccine (2010) 1.19
Barriers and facilitators of pneumococcal vaccination among the elderly. Vaccine (2003) 1.19
Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults. J Gen Intern Med (2014) 1.17
Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine (2008) 1.14
To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling. PLoS One (2010) 1.13
Predictors of colorectal cancer screening in diverse primary care practices. BMC Health Serv Res (2006) 1.11
Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine. Pediatr Infect Dis J (2013) 1.10
Barriers to and facilitators of child influenza vaccine - perspectives from parents, teens, marketing and healthcare professionals. Vaccine (2012) 1.09
Knowledge and beliefs about influenza, pneumococcal disease, and immunizations among older people. J Am Geriatr Soc (2002) 1.08
Forecasting the economic value of an Enterovirus 71 (EV71) vaccine. Vaccine (2010) 1.07
Influenza and other respiratory virus infections in outpatients with medically attended acute respiratory infection during the 2011-12 influenza season. Influenza Other Respir Viruses (2014) 1.07
Parental perspectives on influenza vaccination of children with chronic medical conditions. J Natl Med Assoc (2006) 1.06
Risk of invasive pneumococcal infections among working age adults with asthma. Thorax (2010) 1.05
From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination. Vaccine (2011) 1.05
Determinants of adult vaccination at inner-city health centers: a descriptive study. BMC Fam Pract (2006) 1.05
Augmenting transport versus increasing cold storage to improve vaccine supply chains. PLoS One (2013) 1.04
Success of the 4 pillars toolkit for influenza and pneumococcal vaccination in adults. J Healthc Qual (2013) 1.04
Maintaining vaccine delivery following the introduction of the rotavirus and pneumococcal vaccines in Thailand. PLoS One (2011) 1.04
Invasive group B streptococcal infections in Finland: a population-based study. Emerg Infect Dis (2003) 1.03
How influenza vaccination policy may affect vaccine logistics. Vaccine (2012) 1.03
Predictors of pneumococcal polysaccharide vaccination among patients at three inner-city neighborhood health centers. Am J Geriatr Pharmacother (2005) 1.02
Modeling the economic value of a Chagas' disease therapeutic vaccine. Hum Vaccin Immunother (2012) 1.02
Improving influenza vaccination rates in the workplace: a randomized trial. Am J Prev Med (2009) 1.01
Parental perspectives on influenza immunization of children aged 6 to 23 months. Am J Prev Med (2005) 1.01
Shortage of influenza vaccine in 2000-2001: did it change patient beliefs? Am J Prev Med (2003) 1.01
Beliefs and attitudes about influenza immunization among parents of children with chronic medical conditions over a two-year period. J Urban Health (2006) 1.00
Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect Dis (2008) 0.98
Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. J Womens Health (Larchmt) (2010) 0.98
Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults. Am J Prev Med (2013) 0.98
Changes in parents' perceptions of infant influenza vaccination over two years. J Natl Med Assoc (2007) 0.97
Effect of vaccine shortages on timeliness of pneumococcal conjugate vaccination: results from the 2001-2005 National Immunization Survey. Pediatrics (2007) 0.97
Use of standing orders for adult influenza vaccination a national survey of primary care physicians. Am J Prev Med (2011) 0.97
Racial differences in beliefs about genetic screening among patients at inner-city neighborhood health centers. J Natl Med Assoc (2006) 0.96
Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia. J Gen Intern Med (2013) 0.95
Improving influenza vaccination rates of high-risk inner-city children over 2 intervention years. Ann Fam Med (2006) 0.95
Predictors of lower endoscopy use among patients at three inner-city neighborhood health centers. J Urban Health (2006) 0.95